| COVID-19 ethics and research KM Meagher, NW Cummins, AE Bharucha, AD Badley, LL Chlan, ... Mayo Clinic Proceedings 95 (6), 1119-1123, 2020 | 78 | 2020 |
| Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment GE Henderson, HL Peay, E Kroon, RJ Cadigan, K Meagher, T Jupimai, ... Journal of medical ethics 44 (4), 270-276, 2018 | 63 | 2018 |
| Characteristics and utilisation of the Mayo Clinic Biobank, a clinic-based prospective collection in the USA: cohort profile JE Olson, E Ryu, MA Hathcock, R Gupta, JT Bublitz, PY Takahashi, ... Bmj Open 9 (11), e032707, 2019 | 39 | 2019 |
| Precisely where are we going? Charting the new terrain of precision prevention KM Meagher, ML McGowan, RA Settersten Jr, JR Fishman, ET Juengst Annual Review of Genomics and Human Genetics 18, 369-387, 2017 | 36 | 2017 |
| Going off antiretroviral treatment in a closely monitored HIV “cure” trial: longitudinal assessments of acutely diagnosed trial participants and decliners GE Henderson, M Waltz, K Meagher, RJ Cadigan, T Jupimai, S Isaacson, ... Journal of the International AIDS Society 22 (3), e25260, 2019 | 28 | 2019 |
| Is enhancement the price of prevention in human gene editing? ET Juengst, GE Henderson, RL Walker, JM Conley, D MacKay, ... The CRISPR Journal 1 (6), 351-354, 2018 | 20 | 2018 |
| How biomedical HIV prevention trials incorporate behavioral and social sciences research: a typology of approaches A Corneli, K Meagher, G Henderson, H Peay, S Rennie AIDS and Behavior 23, 2146-2154, 2019 | 18 | 2019 |
| Considering virtue: public health and clinical ethics KM Meagher Journal of Evaluation in Clinical Practice 17 (5), 888-893, 2011 | 17 | 2011 |
| Integrating public health and deliberative public bioethics: Lessons from the human genome project ethical, legal, and social implications program KM Meagher, LM Lee Public Health Reports 131 (1), 44-51, 2016 | 16 | 2016 |
| Reexamining the ethics of human germline editing in the wake of scandal KM Meagher, MA Allyse, Z Master, RR Sharp Mayo Clinic Proceedings 95 (2), 330-338, 2020 | 15 | 2020 |
| Ethical challenges in COVID-19 Biospecimen research: perspectives from institutional review board members and Bioethicists MI Lapid, KM Meagher, HC Giunta, BL Clarke, Y Ouellette, TL Armbrust, ... Mayo Clinic Proceedings 96 (1), 165-173, 2021 | 13 | 2021 |
| Multiple marginalizations: What bioethics can learn from black feminism AW Cheema, KM Meagher, RR Sharp The American Journal of Bioethics 19 (2), 1-3, 2019 | 13 | 2019 |
| Too much of a good thing? Overdiagnosis, or overestimating risk in preventive genomic screening KM Meagher, JS Berg Personalized Medicine 15 (5), 343-346, 2018 | 12 | 2018 |
| Costa Rica's ‘White Legend’: How racial narratives undermine its Health Care System L CAMPO‐ENGELSTEIN, K Meagher Developing world bioethics 11 (2), 99-107, 2011 | 12 | 2011 |
| Communicating unexpected pharmacogenomic results to biobank contributors: a focus group study KM Meagher, SH Curtis, S Borucki, A Beck, T Srinivasan, A Cheema, ... Patient Education and Counseling 104 (2), 242-249, 2021 | 10 | 2021 |
| Assessing the implications of positive genomic screening results M Waltz, KM Meagher, GE Henderson, KAB Goddard, K Muessig, JS Berg, ... Personalized medicine 17 (2), 101-109, 2020 | 9 | 2020 |
| A new governance approach to regulating human genome editing JM Conley, AM Davis, GE Henderson, ET Juengst, KM Meagher, ... North Carolina journal of law & technology 22 (2), 107, 2020 | 7 | 2020 |
| At a moment’s notice: community advisory board perspectives on biobank communication to supplement broad consent KM Meagher, SH Curtis, KO Gamm, EJ Sutton, JB McCormick, RR Sharp Public health genomics 23 (3-4), 77-89, 2020 | 5 | 2020 |
| Grudging trust and the limits of trustworthy biorepository curation KM Meagher, ET Juengst, GE Henderson The American Journal of Bioethics 18 (4), 23-25, 2018 | 4 | 2018 |
| The new precision stewards? KM Meagher, S Watson, GA Suh, A Virk Journal of Personalized Medicine 12 (8), 1308, 2022 | 3 | 2022 |
